Publications by authors named "Mitra Deyhimi"
Article Synopsis
- Acute myeloid leukemia (AML) is characterized by the malignant growth of defective precursor cells, often involving FLT3 mutations, which worsen prognosis.
- Quizartinib is a second-generation FLT3 inhibitor approved by the FDA for treating relapsed or refractory AML with FLT3/ITD mutations and has been effective in clinical trials since 2013.
- This review covers Quizartinib's working mechanism, its effectiveness alone or with chemotherapy, potential drug interactions, side effects, resistance issues, and future research avenues.
Background: Obesity makes migraine more prevalent and severe. Serum level of calcitonin gene-related peptide (CGRP) is associated with the severity of migraine attacks. Although the effect of weight and bariatric surgery has been studied on migraine, the role of CGRP in migraine remission after weight loss surgery needs more investigation.
View Article and Find Full Text PDF